Cited by 434Cardiac Ischemia and ReperfusionNitric Oxide and Endothelin EffectsNeurological Disorders and Treatments

The ubiquitous role of nitric oxide in cardioprotection

Jones, Steven P., Bolli, Roberto·2006·Journal of Molecular and Cellular Cardiology

Abstract

In recent years, major advances have been made toward understanding the role of nitric oxide (NO) in the ischemic biology of the heart. It is now clear that NO, either endogenous or exogenous, represents one of the most important defenses against myocardial ischemia-reperfusion injury. The purpose of this review is to provide an update on the cardioprotective actions of NO, with particular emphasis on the function of the inducible isoform of NO synthase (iNOS) and on the role of mitochondria in NO-mediated protection. This essay underscores some of the more prominent areas of ischemic biology that relate to NO, such as ischemic preconditioning, pharmacological cardioprotection, and gene therapy. The hypothesis that the late phase of preconditioning is mediated by increased iNOS activity resulting in enhanced NO bioavailability, first proposed by our group, is now widely accepted and can be regarded as a proven hypothesis. Likewise, the burgeoning field of postconditioning may share such a requirement for NO. Various drugs (e.g. statins, ACE inhibitors, angiotensin-receptor blockers, etc.) also produce salubrious effects in experimental models of myocardial infarction via their enhancement of NO bioavailability. Thus, NO appears to be a common mediator of the protection afforded by a wide array of seemingly unrelated pharmacological and nonpharmacological interventions, underscoring its fundamental role as a ubiquitous defense of the heart against ischemia and reperfusion. This review challenges the conventional wisdom that iNOS is deleterious during myocardial ischemia-reperfusion and instead proposes the concept that iNOS, when expressed in cardiac myocytes, is a profoundly protective protein. We also emphasize the emerging importance of the mitochondrial actions of NO. Although the precise molecular events remain to be defined, we propose that NO interacts with components of the electron transport chain and/or the mitochondrial permeability transition pore to limit post-ischemic myocardial damage, and that this action potentially provides a fundamental molecular explanation for the mechanism of NO-mediated cardioprotection.

Integrity signals

Registry

Crossref · 10.1016/j.yjmcc.2005.09.011

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • NOS ability to generate NO during ischemia is compromised because of the requirement for oxygen, BH4, and other co-factors that may be limiting during tissue ischemia.

    “Although NO is known to protect tissues from ischemic injury, the ability of nitric oxide synthases to generate NO during ischemia is compromised because of the requirement for oxygen, BH4, and other co-factors which may be limiting during tissue ischemia [29–31].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jones, S. P., & Bolli, R.
Affiliations
University of Louisville (US)
Corresponding author
Jones, Steven P.
Venue
Journal of Molecular and Cellular Cardiology
Publisher
Elsevier BV
Published
2006-01
Volume
40
Issue
1
Pages
16-23
ISSN
0022-2828 (ISSN-L)
OpenAlex
W1966726553
Cited by
434
References
84
Citations by year
2026: 1 · 2025: 2 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 17 · 2020: 8 · 2019: 6 · 2018: 20 · 2017: 16 · 2016: 14 · 2015: 17 · 2014: 22 · 2013: 24 · 2012: 35
FWCI
25.85
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Molecular and Cellular Cardiology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Heart Association
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (P01HL078825, R01HL070897, HL 78825, HL 55757, HL-68088, HL70897, R01HL068088)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Cardiac Ischemia and Reperfusion
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
Keywords
nitric oxide, cardioprotection, myocardial ischemia-reperfusion injury, inducible nitric oxide synthase, ischemic preconditioning, postconditioning, NO bioavailability, mitochondrial permeability transition pore, electron transport chain, statins, ACE inhibitors, angiotensin receptor blockers, gene therapy, myocardial infarction
MeSH terms
Animals, Heart, Humans, Mitochondria, Heart, Myocardial Infarction, Myocardium, Nitric Oxide, Nitrites, Ischemic Preconditioning, Myocardial, Protective Agents, Nitric Oxide Donors, Nitric Oxide Synthase Type II

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review